Filana Therapeutics
FLNA
40 hedge funds and large institutions have $24.8M invested in Filana Therapeutics in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 8 closing their positions.
700% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $267K
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
29% more funds holding
Funds holding: 31 → 40 (+9)
3% more capital invested
Capital invested by funds: $24.2M → $24.8M (+$608K)
2.37% less ownership
Funds ownership: 26.68% → 24.31% (-2.4%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.32M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.07M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.99M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.97M |
| 5 |
Millennium Management
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.4M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.35M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.22M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$488K |
| 5 |
Two Sigma Investments
New York
|
-$383K |
FLNA Hedge Fund Activity: Q1 2020 in Review
40 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2020, worth a combined $24.8M — up 2.5% from $24.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FLNA positions and 8 closed out — a net gain of 11 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.32M. The largest seller was Renaissance Technologies, cutting an estimated $2.4M.
- 40 institutional investors held Filana Therapeutics (FLNA) as of Q1 2020, up from 31 in Q4 2019.
- Funds reported $24.8M of Filana Therapeutics stock for Q1 2020, up 2.5% quarter-over-quarter.
- 19 funds opened new Filana Therapeutics positions in Q1 2020 and 8 closed out, a net change of +11 holders.
- The largest Filana Therapeutics buyer in Q1 2020 was Vanguard Group, an estimated $4.32M added.
- The largest Filana Therapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $2.4M sold.
Based on aggregated 13F filings for Q1 2020.